METAglut1™ is the solution to a major unmet need to aid diagnose children & adults
thanks to a non invasive, fast and affordable test for a
damaging disease that can be treatable.
Want to receive updates and news about METAglut1™:
Glut1DS, or De Vivo disease,
is a rare neurometabolic syndrome caused by
a defect in the glucose transporter type 1 (Glut1),
resulting in a cerebral energy deficit.
The disease is linked to mutations in the SLC2A1
gene coding for the GLUT1 protein, mostly
heterozygous dominant and de novo.
of patients are currently
Mean age at diagnosis
is 8 years old
Glut1DS is characterized by a
wide phenotypic spectrum
with a combination and severity of symptoms that greatly vary from one patient to another.
Early Detection is Key
Treatable with a ketogenic diet (KD)
Late diagnosis leads to
irreversible brain damage
“It is essential to diagnose as early as possible to allow prompt compensation,
through the Ketogenic Diet, for the brain’s lack of fuel…”
“Early identification of children with the disease is important in order to avoid submitting them to possibly ineffective or potentially detrimental treatments with anticonvulsants”
De Giorgis, P. Veggiotti / Seizure 22 (2013) 803–811
– GLUT1 deficiency syndrome 2013: Current state of the art.
METAglut1™
A direct quantification of GLUT1
on erythrocytes
Equivalent to glycorrhachia
Sensitivity »80%
Specificity >99%
PPV =90%
NPV =97%
*Results published in
Mochel F. et al. Prospective Multicenter Validation of
a Simple Blood Test for the Diagnosis of Glut1
Deficiency Syndrome. Neurology. 2023 Jun
6;100(23):e2360-e2373
METAglut1™ used as a first line simple test
to search for Glut1DS patients**
** Strategy published in the journal Neurology* and recommended by the HAS: Avis n°2023.0011/AC/SEAP du 30 mars 2023 du collège de la Haute Autorité de santé relatif à l’inscription sur la liste des actes et prestations mentionnée à l’article L. 162-1-7 du code de la sécurité sociale du test METAglut1™
1: METAglut1™ is prescribed by neuropediatricians, neurologists or geneticists.
2: Blood draw is performed at the hospital, clinic or diagnostic laboratory, in common EDTA vacutainer tubes.
No need for fasting. Samples are stored at 4°C and stored for up to 7 days.
3: The hospital, clinic or diagnostic laboratory performs the protocol from the METAglut1™ kit. Samples are processed through flow cytometry.
A report is automatically generated with error detection and/or warnings if any.
A copy of the results is provided to the prescriber.
Cerba Laboratory and the Bichat Hospital daily perform the METAglut1™ test in France.
Request forms to perform the test in France by those two partners are available down below:
April 2023
Green light and approval from HAS to facilitate reimbursement of METAglut1™ test in France
“METAglut1™ is a valuable addition to the diagnostic arsenal for Glut1DS, and is ascribed a high clinical added value”
(ASA 2)
METAglut1™ is on the market in France, Belgium, and Luxembourg
thanks to our partnership with a leading European Testing Lab, CERBA Laboratoire
First In Vitro diagnostic test
developed from our
METAdiag platform
& using our
proprietary biomarkers
In Vitro Diagnostic Medical Device
to aid the early diagnosis of the
Glut1 Deficiency Syndrome (Glut1DS) a rare neuropediatric disease
(CE marked)
The test has received
funding from the European Union’s Horizon 2020 research and innovation program
(No 806038)